Inventor · disambiguated record
Jason Pinkstaff
Also filed as: PINKSTAFF JASON · PINKSTAFF JASON K
31 granted patents·10 pending applications·379 citations·filing 2001–2024
97Inventor score
Top patents by PatentIndex Score
41 records- 0198US8012931B2Modified FGF-21 polypeptides and their usesAMBRX INC·Filed 2008·Granted Sep 6, 2011·76 cites·52 claims
- 0296US10253083B2Therapeutic uses of modified relaxin polypeptidesAMBRX INC·Filed 2016·Granted Apr 9, 2019·11 cites·20 claims
- 0396US8383365B2Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivativesAMBRX INC·Filed 2011·Granted Feb 26, 2013·48 cites·60 claims
- 0495US10751391B2Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acidAMBRX INC·Filed 2019·Granted Aug 25, 2020·6 cites·24 claims
- 0595US8735539B2Relaxin polypeptides comprising non-naturally encoded amino acidsKRAYNOV VADIM·Filed 2011·Granted May 27, 2014·36 cites·58 claims
- 0694US10702588B2Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chainAMBRX INC·Filed 2018·Granted Jul 7, 2020·7 cites·20 claims
- 0794US9975936B2Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acidsAMBRX INC·Filed 2016·Granted May 22, 2018·12 cites·20 claims
- 0894US9567386B2Therapeutic uses of modified relaxin polypeptidesAMBRX INC·Filed 2013·Granted Feb 14, 2017·14 cites·12 claims
- 0994US9079971B2Modified FGF-21 polypeptides comprising non-naturally occurring amino acidsAMBRX INC·Filed 2013·Granted Jul 14, 2015·19 cites·39 claims
- 1093US9517273B2Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acidsAMBRX INC·Filed 2015·Granted Dec 13, 2016·15 cites·20 claims
- 1193US7468275B2Synthetic internal ribosome entry sites and methods of identifying sameSCRIPPS RESEARCH INST·Filed 2001·Granted Dec 23, 2008·58 cites·31 claims
- 1292US9962450B2Method of treating heart failure with modified relaxin polypeptidesAMBRX INC·Filed 2016·Granted May 8, 2018·9 cites·21 claims
- 1392US8329869B2Modified interferon beta polypeptides and their usesKRAYNOV VADIM·Filed 2012·Granted Dec 11, 2012·21 cites·6 claims
- 1491US9452222B2Nucleic acids encoding modified relaxin polypeptidesAMBRX INC·Filed 2014·Granted Sep 27, 2016·14 cites·19 claims
- 1590US8114630B2Modified interferon beta polypeptides and their usesKRAYNOV VADIM·Filed 2008·Granted Feb 14, 2012·18 cites·4 claims
- 1687US2024189392A1Modified Relaxin Polypeptides and Their UsesAMBRX INC·Filed 2023·Application pending·0 cites
- 1786US10961291B2Modified FGF-21 polypeptides and their usesAMBRX INC·Filed 2019·Granted Mar 30, 2021·1 cites·26 claims
- 1884US10954270B2Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivativesAMBRX INC·Filed 2017·Granted Mar 23, 2021·2 cites·13 claims
- 1984US10377805B2Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their usesAMBRX INC·Filed 2018·Granted Aug 13, 2019·2 cites·21 claims
- 2084US9796754B2Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivativesMIAO ZHENWEI·Filed 2012·Granted Oct 24, 2017·8 cites·56 claims
- 2181US11786578B2Modified relaxin polypeptides and their usesAMBRX INC·Filed 2022·Granted Oct 17, 2023·0 cites·19 claims
- 2281US2023028168A1Modified Relaxin Polypeptides and Their UsesAMBRX INC·Filed 2022·Application pending·0 cites
- 2380US2025002595A1Anti-CD70 Antibody Drug ConjugatesAMBRX INC·Filed 2024·Application pending·0 cites
- 2477US11993637B2Modified FGF-21 polypeptides with non-naturally encoded amino acidsAMBRX INC·Filed 2021·Granted May 28, 2024·0 cites·20 claims
- 2575US12037405B2Anti-CD70 antibody drug conjugatesAMBRX INC·Filed 2022·Granted Jul 16, 2024·0 cites·19 claims
- 2674US9938333B2Modified leptin polypeptides and their usesKRAYNOV VADIM·Filed 2009·Granted Apr 10, 2018·2 cites·9 claims
- 2773US11311605B2Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptidesAMBRX INC·Filed 2020·Granted Apr 26, 2022·0 cites·24 claims
- 2873US2022411469A1Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivativesAMBRX INC·Filed 2022·Application pending·0 cites
- 2972US11439710B2Nucleic acids encoding modified relaxin polypeptidesAMBRX INC·Filed 2020·Granted Sep 13, 2022·0 cites·20 claims
- 3068US11459392B2Anti-CD70 antibody drug conjugatesAMBRX INC·Filed 2018·Granted Oct 4, 2022·0 cites·16 claims
- 3168US11420999B2Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivativesAMBRX INC·Filed 2021·Granted Aug 23, 2022·0 cites·11 claims
- 3267US2024263160A1Targeted Therapeutic Lysosomal Enzyme Fusion Proteins, Associated Formulations and Uses ThereofBIOMARIN PHAMACEUTICAL INC·Filed 2024·Application pending·0 cites
- 3364US2022251526A1Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereofBIOMARIN PHARM INC·Filed 2022·Application pending·0 cites
- 3463US2011015345A1Modified FGF-23 Polypeptides and Their UsesAMBRX INC·Filed 2009·Application pending·0 cites
- 3561US12214015B2Use of c-type natriuretic peptide variants to treat osteoarthritisBIOMARIN PHARM INC·Filed 2021·Granted Feb 4, 2025·0 cites·18 claims
- 3656US10208123B2Anti-CD70 antibody drug conjugatesAMBRX INC·Filed 2013·Granted Feb 19, 2019·0 cites·4 claims
- 3755US11345904B2Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereofBIOMARIN PHARM INC·Filed 2017·Granted May 31, 2022·0 cites·20 claims
- 3846US11202819B2Use of C-type natriuretic peptide variants to treat osteoarthritisBIOMARIN PHARM INC·Filed 2016·Granted Dec 21, 2021·0 cites·17 claims
- 3944US2015080559A1Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin DerivativesAMBRX INC·Filed 2012·Application pending·0 cites
- 4043US2015152187A1Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand PolypeptidesAMBRX INC·Filed 2013·Application pending·0 cites
- 4137US2019201491A1Bovine fibroblast growth factor 21 and ketosis in dairy cattleELANCO US INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jason Pinkstaff files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →